Halfway through a year Allergan execs have called "pivotal" for Kybella, one analyst describes the product’s launch as “meh.”
The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.
Investors are prepping for AstraZeneca's forthcoming Mystic data, which could shift the I-O landscape and AZ's fortunes, too.
Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?
The FDA has approved Portola Pharmaceuticals’ factor Xa inhibitor Bevyxxa, but now the company is facing plenty of challenges as it gets the drug off the…
Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.
Novo Nordisk can now say its new insulin Tresiba poses no increased heart risks over Sanofi's Lantus—and it’s got some advantages, too.
Sanofi and Regeneron, battling Amgen in the PCSK9 field, boast new data suggesting Praluent can safely cut "bad" cholesterol in high-risk diabetes…
Who's got the edge in the hot PCSK9 case after court arguments? Amgen has an 80% shot, one analyst said. Nope, Regeneron and Sanofi, says another.
Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.